This has led to EGFR-targeted agents, such as the EGFR tyrosine kinase inhibitor (EGFR-TKI) gefitinib (‘Iressa’), being developed for the treatment of non-small-cell lung cancer (NSCLC). Here, EGFR is linked to non-small cell lung carcinoma.